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infection in the HIV population of Nepal
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Thupten K. Lama5, Mamun Al Mahtab6, Amna Subhan Butt7, Sheikh Mohammad Fazle Akbar8, Nirmal Aryal9,
Sapana Karn10, Krishna Das Manandhar9 and Birendra Prasad Gupta9*
Abstract
Background: Infection with the hepatitis E virus (HEV) can cause acute hepatitis in endemic areas in immune-
competent hosts, as well as chronic infection in immune-compromised subjects in non-endemic areas. Most studies
assessing HEV infection in HIV-infected populations have been performed in developed countries that are usually
affected by HEV genotype 3. The objective of this study is to measure the prevalence and risk of acquiring HEV
among HIV-infected individuals in Nepal.
Methods: We prospectively evaluated 459 Human Immunodeficiency Virus (HIV)-positive individuals from Nepal, an
endemic country for HEV, for seroprevalence of HEV and assessed risk factors associated with HEV infection. All
individuals were on antiretroviral therapy and healthy blood donors were used as controls.
Results: We found a high prevalence of HEV IgG (39.4%) and HEV IgM (15.3%) in HIV-positive subjects when compared
to healthy HIV-negative controls: 9.5% and 4.4%, respectively (OR: 6.17, 95% CI 4.42–8.61, p < 0.001 and OR: 3.7, 95% CI
2.35–5.92, p < 0.001, respectively). Individuals residing in the Kathmandu area showed a significantly higher HEV IgG
seroprevalance compared to individuals residing outside of Kathmandu (76.8% vs 11.1%, OR: 30.33, 95% CI 18.02–51.04,
p = 0.001). Mean CD4 counts, HIV viral load and presence of hepatitis B surface antigen correlated with higher HEV IgM
rate, while presence of hepatitis C antibody correlated with higher rate of HEV IgG in serum. Overall, individuals with
HEV IgM positivity had higher levels of alanine aminotransferase (ALT) than IgM negative subjects, suggesting active
acute infection. However, no specific symptoms for hepatitis were identified.
Conclusions: HIV-positive subjects living in Kathmandu are at higher risk of acquiring HEV infection as compared to
the general population and to HIV-positive subjects living outside Kathmandu.
Keywords: HIV, Blood donor, HEV, Kathmandu, Immunocompromised
Background
Infection with the hepatitis E virus (HEV) is the most
frequent cause of acute hepatitis among adults in devel-
oping countries with poor sanitation and hygiene [1, 2].
Four genotypes of the virus have been identified with
different epidemiological and clinical characteristics and
are capable of infecting and causing disease in human
[3]. HEV genotype 1 and 2 are restricted to human and
is associated with consumption of contaminated water,
which consequently leads to occasional outbreaks or
sporadic acute hepatitis cases in developing countries.
HEV genotypes 3 and 4 are considered zoonotic and trans-
mission is related to consumption of raw meat products or
farming. These genotypes cause sporadic acute hepatitis in
industrialized nations and occasionally can progress into a
chronic infection in immunosuppressed hosts [4, 5]. Nepal
is an endemic region for HEV, particularly genotype 1, and
repeated epidemic outbreaks have been documented since
1973 [6, 7]. Sporadic cases of acute hepatitis E occur in-
between these major epidemics and account for 50% of
acute hepatitis cases in the country [8].
The clinical course and prevalence of HEV infection in
subjects infected with human immunodeficiency virus
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(HIV) in endemic regions has not been well established.
Conflicting reports exist regarding the susceptibility to HEV
infection in HIV-positive subjects from different areas of
world [5, 9, 10]. Similarly, the course and severity of HEV
infection in HIV-infected subjects is a matter of debate:
while some studies report unrecognized self-limiting dis-
ease, others report chronic infection and rapid progression
to cirrhosis [11, 12]. Nepal has nearly 40,000 people living
with HIV making a prevalence rate of 0.2% amongst adults
[13]. HIV-infected persons tend to be socially marginalized
and often have poor access to acceptable sanitary standards,
therefore possibly being at higher risk for HEV infection. In
this study, we addressed HEV infection in a cohort of HIV-
infected subjects enrolled in the antiretroviral treatment
program of Nepal. We explored risk factors for HEV infec-
tion in HIV-positive subjects and the relationship between
immune parameters and characteristics of HEV infection.
Methods
Study subjects
This study was conducted among HIV-positive subjects
from six districts of Nepal (Kathmandu, Lalitpur, Kaski,
Sunsari, Bharatpur and Parsa) attending their respective
antiretroviral therapy (ART) centers under the National
ART program of Nepal, between January 2015 to March
2015. Six hundred and thirteen subjects visited the center
during the study period; out of which 459 subjects were
18 years or older, and consented to participate in the
study. A single time-point assessment and blood sample
collection was done to obtain demographic, virological,
clinical and biochemical data. Demographic and clinical
data were recorded in a predesigned questionnaire. Pa-
tients with antibodies against the hepatitis C virus (HCV)
were considered as co-infected irrespective of whether
HCV RNA amplification was performed. A preliminary
letter with some of the preliminary findings pertaining to
HEV IgM was recently published by our group [14].
As controls, we used blood samples and demographic
data of 581 healthy voluntary blood donors aged ≥18 years
from the central blood bank, Kathmandu, Nepal. These
blood samples were collected between February and
March 2014 after informed consent for our another study
to address HEV in healthy donors, and has been described
in detail before [15]. The control group constituted 401
male and 180 females. Among the screened population,
37 were from Kathmandu valley and 544 were from out-
side the valley. Written consent was received from all par-
ticipants and the study was approved by the Nepal Health
Research Council ethical review board.
Laboratory analysis
Blood was collected in EDTA tubes (Becton Dickinson,
USA) and CD4 counts were determined using the FACS
Count system (Becton Dickinson, USA) within 3 h of
collection. Similarly, samples collected in Gel clot vials
were centrifuged and sera were transferred to eppendorf
tubes and stored at −20° Celsius. Biochemical assays for
Alanine aminotransferase (ALT), Aspartate aminotrans-
ferase (AST) and Gamma glutamyltranspeptidase (GGT)
were done using Bio-Slide Technology (J&J, USA). The
serology for anti-HEV IgM and anti-HEV IgG was per-
formed using ELISA (Wantai Biological Pharmacy Enter-
prise, China). ELISA was undertaken in accordance with
the manufacturer’s instructions. Samples with anti-HEV
sample rate/cutoff rate (S/CO) ratios >1 were considered
seropositive. HBsAg was assayed using Abbott-AuszymeMc
(Abbott Laboratories, USA) and anti-HCV was performed
by HCV ELISA (Ortho Diagnostic Systems). HIV RNA was
isolated using the Nucleospin viral RNA isolation kit
(MACHEREY-NAGEL, Germany) according to the
manufacturer’s instruction. For viral RNA amplification
and cDNA preparation artus HI Virus-1 QS-RGQ Kit
(QIAGEN, Germany) was used and primers were sup-
plied by the manufacturer as complete master mix.
The standard protocol for HEV RNA assay was adapted
from previously described study by Jothikumar et al. [16].
HEV RNA was purified from 50 μL of serum and the
GenMagScript One-Step RT-PCR Kit was used for detec-
tion. The 25 μL reaction mixture contained 12.5 μL of 2X
One-Step RT-PCR reaction buffer (Genmagbio, Beijing,
China), 0.2 μL of GenMagScript RT Enzyme Mix, 5 μL of
RNA, and primers (forward primer: BDHEVF (5′-GGTG
GTT TCTGGGGTGAC-3′) and reverse primer: BDHEVR
(5′-A GGGGTTGGTTGGATGAA-3′) and probe (BDHEVP;
5′-TGATTCTCAGCCCTTCGC-3′) at concentrations
of 200 nM. Additionally, internal controls, supplied in
the kit (GenMagScript, China), were used to identify
possible PCR inhibition as detected by fluorescence
channel orange in Rotor gene Q. As an exogenous internal
control sequence, lambda gene PCR product (278-bp) was
added to the reaction mixture.
Statistical analyses
Data was entered and analyzed using SPSS software ver-
sion 23.0. Frequencies were calculated for categorical
variables and mean ± SD were calculated for quantitative
variables. P values of <0.05 were considered significant,
unless described otherwise. Odds ratios (OR) with 95%
confidence intervals were calculated. Categorical variables
were compared using the chi-squared test, while the T test
was used for comparing continuous variables. Spearman’s
correlation coefficient was used to determine the degree
of correlation between continuous variables.
Results
Four hundred and fifty-nine HIV-positive subjects and
581 blood donors (controls) were analyzed. Their demo-
graphic profiles are presented in Table 1. Seventy of 459
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(15.3%) HIV-positive subjects were reactive for anti-
HEV IgM as compared to 4.4% in the HIV-negative con-
trol (blood donor) group [p < 0.001; OR: 3.7 (2.35–5.92)].
Anti-HEV IgG was positive in 181 (39.4%) of the HIV-
positive subjects as compared to 56 (9.5%) of blood do-
nors [p < 0.001; OR: 6.17 (4.42–8.61)]. Age specific
prevalence rates of both anti-HEV IgM and IgG were
significantly higher in HIV-infected subjects as com-
pared to control groups for individuals younger than
20 years, between 20 and 30 years and between 31 and
40 years of age (Fig. 1). Moreover, for anti-HEV IgG, but
not IgM, the prevalence rates were also significant be-
tween 41 and 50 and 51–60 years of age (Fig. 1).
We noticed a significant difference in the prevalence
of anti-HEV IgG and IgM among HIV-positive study
subjects living in Kathmandu, the capital of Nepal, and
those residing outside of Kathmandu (Fig. 2). Overall
anti-HEV IgG prevalence was 76.8% in HIV-positive
subjects living in Kathmandu valley as compared to
11.1% of subjects living outside Kathmandu [p = 0.001;
OR: 30.33 (18.02–51.04)]. Similarly, anti-HEV IgM was
detected in 28.8% of HIV-positive subjects living in
Kathmandu Valley as compared to 4.9% of those living
outside Kathmandu [p = 0.001; OR: 7.71(4.07–14.58)].
We performed HEV PCR on samples of all 70 HIV-
positive individuals and 27 blood donors that were
Table 1 Characteristics of study subjects and comparison between anti-HEV IgM positive and IgM negative group
Characteristics/ Variables Total HIV+ subjects (N = 459)
N (%) or mean ± SD
Anti-HEV IgM+(N = 70)
N (%) or mean ± SD
Anti-HEV IgM–(N = 389)
N (%) or mean ± SD
P valueb
Age 36.21 ± 10.35 37.41 ± 11.02 35.99 ± 10.19 0.318
Gender (Male) 274 (59.69) 40 (57.14) 234 (60.15) 0.510c
Duration of HIV
Diagnosis (years)
4.12 ± 2.57 4.57 ± 2.6 4.04 ± 2.56 0.081d
Living in Kathmandu Valley 198 (43.13) 57 (81.42) 141 (36.24) <0.001c,a
CD4+ count (cells/μL) 301.97 ± 117.75 351.73 ± 109.78 293.02 ± 117.03 <0.001a
ALT 32 ± 12.39 53.9 ± 19.80 28.75 ± 3.79 <0.001a
AST 35 ± 8.15 42.77 ± 14.85 33.60 ± 5.13 <0.001a
HBsAg (n) 24 (5.2) 10 (14.28) 14 (3.59) <0.001c,a
Anti HCV (n) 342 (74.50) 27 (38.57) 315 (80.97) <0.001c,a
Anti-HEV IgG (n) 181 (39.43) 17 (24.28) 164 (42.15) 0.005c, a
HIV Viral load in log cps/ml 2.74 ± 0.46 2.90 ± 0.61 2.71 ± 0.44 0.016a
Abbreviations: CD4- Cluster of differentiations 4; ALT- Alanine aminotransferase; AST- Aspartate aminotransferase; GGT- Gamma glutamyltranspeptidase;
HBsAg- Hepatitis B surface Antigen; HCV- Hepatitis C virus, HEV- Hepatitis E virus, HIV- Human Immunodeficiency virus
aSignificant
bSignificance of difference between anti-HEV IgM+ and IgM– group
cChi squared test
dMann Whitney U test
Fig. 1 Age-specific prevalence of anti-HEV IgM and anti-HEV IgG in control subjects and HIV-infected subjects. Anti HEV IgM: blood donors versus
HIV-positive individuals: age < 20 (p = 0.04); age 21–30 (p = 0.021); age 31–40 (p = 0.00); age 41–50 (p = 0.21); age 51–60 (p = 1.0). Anti HEV IgG: blood
donors versus HIV-positive individuals: age < 20 (p = 0.021); age 21–30 (p = 0.00); age 31–40 (p = 0.00); age 41–50 (p = 0.00); age 51–60 (p = 0.00)
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positive for anti-HEV IgM. Seventeen (24%) of the HIV-
positive individuals and 9 (33%) of the controls showed
positive HEV RNA levels. (Table 2). The age-adjusted
prevalence rates of anti-HEV IgM and anti-HEV IgG in
the control group of healthy blood donors, as well as
HIV-positive subjects living within Kathmandu and
those living outside of Kathmandu are shown in Table 3.
Lower mean CD4 counts, higher HIV viral load (log
copies), higher ALT and AST, presence of HBsAg, and
living-inside-Kathmandu valley were significantly associ-
ated with a higher rate of anti-HEV IgM seropositivity,
while presence of HCV antibody was significantly associ-
ated with HEV IgM seronegativity. In contrast, age, gen-
der and duration of HIV infection were not significantly
associated to anti-HEV IgM status (Table 1).
In multivariate analysis, living-inside-Kathmandu
valley and anti-HCV negativity were independent risk
factors associated with the presence of anti-HEV IgM
positivity in HIV-infected subjects (Table 4). Interest-
ingly, a CD4 count >200/μl, and a HIV viral load >3log
copies/ml were also associated with presence of anti-
HEV IgM. HIV viral load >3 log copies/ml, HCV co-
infection and living-inside-the-Kathmandu valley were
independent risk factors for anti-HEV IgG positivity
(Table 4). The prevalence of anti-HEV IgG in HCV co-
infected subjects was 47.9% as compared 13.7% in
those without co-infection [p < 0.001; OR: 5.88 (3.33–
10.38)] (Fig. 3).
The levels of the serum transaminases ALT and AST
were also significantly higher in anti-HEV IgM positive
subjects as compared to anti-HEV IgM negative HIV pa-
tients, suggesting clinically acute infection in these cases.
Discussion
HEV infection is endemic in Nepal and cases occur in
sporadic and epidemic fashion. The current study shows
that HIV-infected individuals are at higher risk of ac-
quiring acute HEV infection than healthy individuals in
this area. Several studies from developed countries sug-
gest that HEV is not more frequent in HIV-infected sub-
jects compared to healthy controls [5, 10]. Kuniholm et
al. reported that in the United States, HEV genotype 3
caused both acute and chronic HEV infection in HIV-
positive subjects, but it was too rare to recommend rou-
tine surveillance, with only one chronic case in more
than 300 tested individuals [5]. HEV genotype 3 infec-
tion is a food-borne infection and is related to consump-
tion of uncooked meat products. Thus, in developed
countries, distribution of HEV may be determined by
eating habits and methods of processing pork meat [10].
In developing countries like Nepal, HEV is exclusively
caused by genotype 1 infection [6–8, 17]. Contamination
of the drinking water supply by HEV is common in de-
veloping nations and a large population is therefore ex-
posed to the virus [6, 7, 18]. This likely explains the high
prevalence of anti-HEV positivity in both HIV-infected
Fig. 2 Prevalence of IgM and IgG anti-HEV in HIV-infected subjects from Kathmandu and outside Kathmandu Valley: The overall prevalence of
IgM and IgG anti- HEV is higher in Kathmandu valley indicating that HIV-infected individuals living in Kathmandu are immune to HEV
Table 2 Comparison of various combinations of anti HEV IgM and IgG among HIV positive subjects and Blood Donors
Anti HEV antibodies IgM+/IgG+ IgM+/IgG- IgM−/IgG+ IgM−/IgG- HEV RNA+
Blood Donors 9(1.5%) 18(3.1) 47(8.1) 507(87.3) 9(1.5%)
HIV positive Subjects 17(3.7%) 53(11.5%) 164(35.7%) 225(49%) 17(3.7%)
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as well as healthy controls in our study. However,
whether HIV-infected subjects have a higher HEV attack
rate as compared to the general population is not clear.
HIV-infected subjects in Nepal are socially marginalized,
and economically compromised [19]. Poor access to
clean drinking water could possibly explain higher anti-
HEV IgM prevalence in this group regardless of their
immune status.
Our study showed that anti-HEV IgG seroprevalence
was higher in HIV-infected subjects as compared to the
control population. Similar observations were made in
Russia, Argentina and Germany [20–22]. However, re-
cent studies from the United Kingdom and Spain found
that anti-HEV IgG prevalence in HIV-positive and –
negative subjects were not different [10, 23].Further
studies are needed to understand whether this discrepancy
in findings is related to HEV genotype (HEV 1 vs 3), cul-
tural habits of the geographical region or immune status.
Although the entire country of Nepal is listed as endemic
region for HEV infection, most of the major epidemics have
taken place in the Kathmandu Valley. Drinking water pipe-
lines and sewage pipelines run underground close to each
other in Kathmandu Valley. A breach in sewage pipelines
and subsequent fecal contamination of the water supply
leads to major epidemics. Such close proximity of drinking
water supply and sewage pipelines are not seen in most of
the rural areas of Nepal making them less prone to out-
breaks of HEV. Previous studies have demonstrated that
anti-HEV IgG prevalence was high in residents of
Kathmandu valley and remarkably low in other areas of
Nepal [7]. In the current study, age adjusted prevalence of
anti-HEV IgG in HIV-positive subjects was 35% as com-
pared to 8% in the control group. The prevalence of anti-
HEV IgG in our study seems lower than that reported in a
recent study by Izopet et al., which was conducted in a
hospital of Kathmandu valley, which found 47.1% HEV
seroprevalence in non-HIV-infected subjects [24]. When
we segregated our study cohort on the basis of where the
subjects live, the age adjusted prevalence rate of anti-HEV
IgG among HIV-positive subjects from Kathmandu was
65.8%. This value was more in concordance with that in
the general population of Kathmandu as reported by Izopet
et al., but still higher in HIV-infected individuals compared
to controls.
The control group in our study, composed of healthy
blood donors, showed an anti-HEV IgG prevalence of
8.3%, which was in the same range as previously pub-
lished data from Kathmandu [25, 26], but markedly
lower than Izopet et al. [24]. This can be explained by
the fact that 94% of the control group was formed by
people living outside Kathmandu valley. Overall only 2%
of the HIV-positive subjects living in Kathmandu lacked
evidence of recent or remote infection (IgM or IgG posi-
tivity) as compared to 84.6% of subjects living outside
Kathmandu. Recurrent epidemics in Kathmandu along
with high prevalence of both anti-HEV IgM an IgG in
subjects living in Kathmandu as compared to those liv-
ing in other areas clearly indicate that HEV is largely
confined to the Kathmandu valley.
In multivariate analysis, the current study identified
independent risk factors for anti-HEV IgM and IgG
positivity. While HIV viral load >3 log copies/ml and
living in Kathmandu valley were common risk factors
for anti-HEV IgM as well as IgG positivity, HCV co-
infection was found to be a risk factor only for anti-
HEV IgG positivity. Indeed, HCV co-infected subjects
in our cohort showed a much higher evidence of im-
munity to HEV compared to HCV-negative (48% vs
13%). This is rather surprising since the predominant
risk factor for HCV infection in Nepal is intravenous
Table 3 Crude and age-adjusted prevalence rates of anti-HEV IgM and anti-HEV IgG among control group, HIV-positive subjects
living inside and outside Kathmandu
HIV (total) Blood donors HIV (Kathmandu) HIV (Outside Kathmandu)
Anti-HEV IgM Crude prevalence rate 15.31 4.64 28.93 4.9
Age adjusted prevalence rate 17.54 3.6 30.61 4.21
Anti-HEV IgG Crude prevalence rate 39.60 9.63 77.8 23.6
Age adjusted prevalence rate 35.02 8.3 65.89 20.84
Table 4 Multivariate analysis showing independent risk factors for anti-HEV IgM and anti-HEV IgG among HIV-positive subjects
Risk Factors Odds Ratio for Anti-HEV IgM, 95% CI P value† Odds Ratio for Anti-HEV IgG, 95% CI P valueγ
CD4+ count >200cells/μl 5.109 [1.624–16.070] 0.005* 0.67 [.333–1.36] 0.273
Anti HCV Positive status 0.018 [0.006–0.056] <0.001* 5.35 [2.44–11.69] <0.001*
Residing in Kathmandu Valley 44.31 [14.507–135.353] <0.001* 37.73 [20.98–67.87] <0.001*
HIV viral load > 3log cps/ml 3.045 [1.25–7.39] <0.001* 4.43 [1.67–11.73] 0.001*
CI- Confidence interval
*Significant †association between risk factor and presence of anti-HEV IgM in serum of HIV-positive patients
γassociation between risk factor and presence of anti-HEV IgG in serum of HIV-positive patients
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drug use. Whether intravenous drug use poses a risk
for HEV exposure in HCV infected subjects leading to
higher anti-HEV IgG prevalence is not known, and
HEV is not known to be transmitted through blood,
but it is a possibility that needs to be evaluated in fu-
ture studies. Balyan et al. also reported high prevalence
of anti-HEV IgG in Russian HIV-positive subjects and
proposed common risk factors for transmission of both
viruses [20]. Moreover, anti-HEV IgG positivity is
higher in patients undergoing hemodialysis (which is
subjected to frequent blood transfusions) with no clear
explanation [27].
It has been reported that low CD4 counts in HIV-
positive patients are associated with higher anti-HEV
IgG seropositivity [23, 28]. Interestingly, we observed a
higher rate of anti-HEV IgM positivity in subjects with
CD4 counts >200. However, one should be cautious
when interpreting the immune status (i.e. the immuno-
globulin levels) in immunocompromised patients. A
proportion, but not all, of those that tested positive for
HEV IgM showed detectable levels of HEV RNA. This
could be due to a) decrease in RNA levels before nega-
tivization of IgM in acute disease or b) lack of correl-
ation between IgM and HEV viral load. The later
situation has been described before and it is thought to
be due to lack of international standardization of HEV
primers for PCR [29].
HIV-positive subjects with acute HEV infection did
not show marked ALT elevations as seen in immuno-
competent individuals and none of them had bilirubin
>2 mg/dl. Although anti-HEV IgM positive subjects had
higher ALT levels than the remaining group, the degree
of ALT elevation was less than 3 times the upper limit of
normal and none showed symptoms of acute hepatitis.
HEV is a non-cytopathic virus and the damage of hepa-
tocytes is an immune mediated phenomenon. Therefore,
the severity of hepatocyte injury in immunocomprom-
ised hosts might be limited.
Conclusion
HIV-positive subjects living in Kathmandu are at higher
risk of acquiring HEV infection as compared to the gen-
eral population and to HIV-positive subjects living outside
Kathmandu. Even though acute HEV infections are
more frequently seen in HIV-positive subjects, the
resulting health effects are not clear, as it does not seem
to cause clinically evident disease. Further studies are
necessary to understand the long-term implications of
HEV infection in this population.
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